C4 Therapeutics, Inc. (CCCC): Submission of Matters to a Vote of Security Holders
C4 Therapeutics, Inc. (CCCC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. cccc-20260624 0001662579 false 0001662579 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________ FORM 8-K _________________________________________________________________ CUR
How this was made
The 30-second read
Why it matters
Key items were: election of four Class III directors, non-binding say-on-pay approval, ratification of KPMG as independent auditor for FY2026, and approval of an amendment to the 2020 Stock Option and Incentive Plan’s evergreen provision to include outstanding pre-funded warrants in the share count.
Market read
This is governance/stock-plan approval news; it may marginally affect dilution/option overhang expectations but lacks new operating catalysts.
What to watch
The filing includes vote totals but not the size of the evergreen increase or any immediate issuance—so the practical dilution impact may be smaller than investors assume.
Background
The company’s 8-K (Item 5.07) summarizes results from its June 24, 2026 Annual Meeting of Stockholders.
Ticker impact
C4 Therapeutics filed an 8-K reporting Annual Meeting voting results, including director elections, say-on-pay, auditor ratification, and a stock plan evergreen amendment.
Likely limited near-term impact; any effect would be secondary through dilution/option-plan expectations rather than a discrete catalyst.
The filing discloses final vote counts and approval of a stock option plan amendment, but provides no new financial guidance, clinical/regulatory updates, or capital-structure transaction details.
Market effects
Minimal; this is company-specific governance/stock-plan mechanics with no sector-wide signal.
None material indicated; US-listed Nasdaq issuer filing.
None indicated.
Counterpoint
Even without operational updates, evergreen stock-plan amendments can subtly shift dilution expectations; traders focused on overhang could react if they track share-issuance capacity.
Key entities
- public_companyC4 Therapeutics, Inc.
Nasdaq-listed biotech issuer; reported shareholder vote outcomes via SEC Form 8-K.
- auditorKPMG LLP
Ratified as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.